|
|
Cyclophosphamide Improves Scleroderma but Benefits Wane
|
| Link ID |
2079 |
| Title |
Cyclophosphamide Improves Scleroderma but Benefits Wane |
| Url |
http://www.medscape.com/viewarticle/568100?src=rss |
| Description |
One year of treatment with cyclophosphamide results in significant improvements in lung function, skin scores, dyspnea, and quality of life in patients with scleroderma lung disease, new findings indicate. While these effects persist for several months after treatment cessation, they are generally no longer apparent after 24 months. Reuters Health Information |
| Category |
Articles > Pharmacists |
| Keywords |
|
| Date |
Jan 3, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Pharmacists |
| 1. |
Sirolimus Stents Better at Reducing Restenosis
|
|
|
Sirolimus-eluting stents may offer an advantage over bare-metal stents in patients with ST segment elevation myocardial infarction (STEMI), Dutch researchers report in the February 12th issue of the Journal of the American College of Cardiology. Reuters Health Information
|
| 4. |
Montelukast Associated With Churg-Strauss Syndrome but Not the Cause
|
|
|
Although use of the leukotriene receptor antagonist montelukast is associated with a significant risk of Churg-Strauss syndrome (CSS), it is likely "a proxy measure for gradually worsening asthma at an individual level and for the important increase in montelukast exposure in general," researchers conclude in a study published in the August issue of Thorax. Reuters Health Information
|
| 5. |
Aspiration Widespread in Head and Neck Cancer Patients
|
|
|
Aspiration is very common in patients with advanced head and neck cancer, is more severe following chemoradiation therapy, and is often without symptoms, according to Illinois-based researchers. Reuters Health Information
|
|
|
